Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye implant could slow vision loss from dry AMD

NCT ID NCT07668804

Disease control Sponsor: Theratocular Biotek Co. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a biodegradable eye implant called TO-O-1007 for geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The implant slowly releases medication over 6 months to slow disease progression. About 31 adults aged 50 and older will receive either a low-dose, high-dose, or sham injection to evaluate safety and early effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TO-O-1007 implant
What this could lead to
If successful, this could lead to a treatment that slows vision loss from geographic atrophy with fewer injections.
What could go wrong
This is an early phase trial with only 31 people, so safety and effectiveness are not yet proven. The implant may not slow disease progression or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 31 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults ≥50 years, able to provide informed consent and comply with study procedures. 2. Non-foveal GA secondary to dry AMD, confirmed by the central reading center. 3. Total GA area 2.5-17.5 mm² by FAF (≥1.25 mm² for at least one lesion if multifocal). 4. BCVA ≥24 ETDRS letters (\~20/320 Snellen) in the study eye. 5. IOP ≤21 mmHg in the study eye. Exclusion Criteria: 1. Recent participation in intravitreal, GA, or investigational treatment studies. 2. Pregnant or nursing women. 3. High myopia (\>8 D or axial length \>27 mm). 4. Prior AMD treatment or active/secondary CNV in the study eye. 5. Current/prior uveitis. 6. Recent anti-complement therapy. 7. Use of prohibited medications, investigational products, or immunosuppressive therapies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Geographic atrophy due to age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration Geographic Atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Geographic atrophy due to age-related macular degeneration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Launceston Eye Doctors

    RECRUITING

    Launceston, Tasmania (tas), 7250, Australia

  • Retina & Eye Consultants

    RECRUITING

    Hurstville, New South Wales (nsw), 2220, Australia

  • Sydney Retina Clinic & Day Surgery

    RECRUITING

    Sydney, New South Wales (nsw), 2000, Australia